Molecular profiling and characteristics of non-small-cell lung cancer patients in Georgia

被引：1

作者：

Kiladze, Ivane ^{[1
]}

Mariamidze, Elene ^{[2
]}

Baramidze, Anna ^{[3
]}

Lomidze, Mariam ^{[3
]}

Meladze, Ketevan ^{[3
]}

Jeremic, Branislav ^{[4
]}

机构：

[1] Caucasus Med Ctr, Dept Clin Oncol, Tbilisi, Georgia

[2] Res Inst Clin Med, Dept Oncol & Hematol, Tbilisi, Georgia

[3] Res Inst Clin Med, Dept Clin Trials, Tbilisi, Georgia

[4] Univ Kragujevac, Fac Med, Kragujevac, Serbia

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 27期

关键词：

ALK; biomarker testing; EGFR; Georgia; lung cancer; PD-L1; smoking; GROWTH-FACTOR RECEPTOR; HISTOLOGICAL TYPES; CLINICAL-OUTCOMES; CIGARETTE-SMOKING; TARGETED THERAPY; EGFR MUTATIONS; ALK; RISK; EPIDEMIOLOGY; ASSOCIATION;

D O I：

10.2217/fon-2021-0177

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aims: In patients with advanced non-small-cell lung cancer, the correlation between histopathology, smoking status, driver oncogene mutations and PD-L1 overexpression were investigated. Patients and methods: A total of 202 patients were identified. Research was done in Georgia. Results: EGFR mutations were detected in 6% of the tested cases (12/187) and five out of 12 EGFR+ cases had histology consistent with squamous cell carcinoma. No statistically significant correlation was observed between PD-L1 expression, smoking status and clinicopathological characteristics. However, the correlation between smoking status and histology was statistically significant (p = 0.0264), as never-smokers had a higher incidence of adenocarcinoma histology. Conclusion: The study showed a small percentage of EGFR mutations associated with adenocarcinoma histology and revealed a solid existence of this mutation in squamous cell carcinoma histology. A higher incidence of adenocarcinoma histology was observed in never-smokers.

引用

页码：3585 / 3594

页数：10

共 52 条

[1] Amin MB., 2016, AJCC Cancer Staging Manual, V8th
[2] [Anonymous], 2014, CANC INCIDENCE 5 CON
[3] [Anonymous], 2004, WHO CLASSIFICATION T
[4] [Anonymous], 2001, WOM SMOK REP SURG GE, P193
[5] Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer
Azuma, K.
Ota, K.
Kawahara, A.
Hattori, S.
Iwama, E.
Harada, T.
Matsumoto, K.
Takayama, K.
Takamori, S.
Kage, M.
Hoshino, T.
Nakanishi, Y.
Okamoto, I.
[J]. ANNALS OF ONCOLOGY, 2014, 25 (10) : 1935 - 1940
[6] Bidoli, 1999, EPIDEMIOLOGY LUNG CA, P1
[7] Blot W., 1996, Cancer Epidemiology and Prevention, P637
[8] ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC
Casaluce, Francesca
Sgambato, Assunta
Maione, Paolo
Rossi, Antonio
Ferrara, Carmine
Napolitano, Alba
Palazzolo, Giovanni
Ciardiello, Fortunato
Gridelli, Cesare
[J]. TARGETED ONCOLOGY, 2013, 8 (01) : 55 - 67
[9] What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements
Cooper, Wendy A.
O'Toole, Sandra
Boyer, Michael
Horvath, Lisa
Mahar, Annabelle
[J]. PATHOLOGY, 2011, 43 (02) : 103 - 115
[10] Targeted therapies and immunotherapy in non-small-cell lung cancer
Cortinovis, D.
Abbate, M.
Bidoli, P.
Capici, S.
Canova, S.
[J]. ECANCERMEDICALSCIENCE, 2016, 10

← 1 2 3 4 5 6 →